Z-DL-Phe-NHMe | 108477-41-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Z-DL-Phe-NHMe
• 英文别名: N-Methyl L-Cbz-Phenylalaninamide；benzyl N-[1-(methylamino)-1-oxo-3-phenylpropan-2-yl]carbamate
• CAS: 108477-41-4
• 化学式: C₁₈H₂₀N₂O₃
• mdl: MFCD26131150
• 分子量: 312.368
• InChiKey: DEDOGCUYHOPZPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  67.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  Cbz-DL-苯丙氨酸 、 甲胺 生成 Z-DL-Phe-NHMe
  参考文献：
  名称：

  The Reactions of Carbobenzoxyamino Acid Amides with Carbonyl Compounds

  摘要：

  DOI：

  10.1021/jo01063a029

文献信息

• [EN] CANCER CELL SPECIFIC IMAGING PROBES AND METHODS OF USE<br/>[FR] SONDES D'IMAGERIE SPÉCIFIQUES DE CELLULE CANCÉREUSE ET PROCÉDÉS D'UTILISATION
  申请人：RES FOUNDATION FOR THE STATE UNIVERISTY OF NEW YORK

  公开号：WO2015021305A1

  公开（公告）日：2015-02-12

  The present invention provides a compound having the structure: wherein X is an imaging agent containing at least one amine nitrogen; Y is a chemical linker, wherein Y is present or absent, and when present Y is a chemical linker containing at least one amine nitrogen or Y is a para-aminobenzyl alcohol linker; Z is CH3 or CF3 ; R1 is -H, -NR2R3, -NH-C(=0) -R4, -NH-C ( =0) -OR4, -CH2-C ( =0) -NR5R6, - OR7, -CO2R7, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, or heteroaryl, wherein R2, R3, R4, R5, R6 and R7are each, independently, - H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, aikylaryl, heteroaryl, alkylheteroaryl, an amino acid or an oligopeptide; wherein an amine of the amino acid or oligopeptide is substituted or unsubstituted; and n is an integer from 0 to 6; or a diastereomer, enantiomer or pharmaceutically acceptable salt of the compound.

  本发明提供了一种化合物，其结构为：其中X是含有至少一个胺氮的成像剂；Y是化学连接剂，其中Y存在或不存在，当Y存在时，Y是含有至少一个胺氮的化学连接剂或Y是对氨基苯甲醇连接剂；Z是CH3或CF3；R1是-H、-NR2R3、-NH-C（=0）-R4、-NH-C（=0）-OR4、-CH2-C（=0）-NR5R6、-OR7、-CO2R7、C1-6烷基、C2-6烯基、C2-6炔基、芳基或杂环芳基，其中R2、R3、R4、R5、R6和R7分别是独立的-H、C1-6烷基、C2-6烯基、C2-6炔基、杂原子烷基、环烷基、杂环烷基、芳基、烷基芳基、杂环芳基、烷基杂环芳基、氨基酸或寡肽；其中氨基酸或寡肽的胺基被取代或未取代；n是从0到6的整数；或化合物的对映异构体、对映体或药学上可接受的盐。
• NOVEL PRODRUGS FOR SELECTIVE ANTICANCER THERAPY
  申请人：Ueki Nobuhide

  公开号：US20150224208A1

  公开（公告）日：2015-08-13

  The present invention provides a compound having the structure: wherein X is a therapeutic agent containing at least one amine nitogen and the amine nitrogen on the therapeutic agent covalently bonds directly to carbon α; Z is CH 3 or CF 3 ; R 1 is —H, —NR 2 R 3 , —NH—C(═O)—R 4 , —NH—C(═O)—OR 4 , —CH 2 —C(═O)—NR 5 R 6 , —OR 7 , —CO 2 R 7 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, or heteroaryl, wherein R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each, independently, —H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, an amino acid or an oligopeptide; wherein an amine of the amino acid or oligopeptide is substituted or unsubstituted; and n is an integer from 0 to 6; or a diastereomer, enantiomer or pharmaceutically acceptable salt of the compound.
• CANCER CELL SPECIFIC IMAGING PROBES AND METHODS OF USE
  申请人：THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK

  公开号：US20160184459A1

  公开（公告）日：2016-06-30

  The present invention provides a compound having the structure: wherein X is an imaging agent containing at least one amine nitrogen; Y is a chemical linker, wherein Y is present or absent, and when present Y is a chemical linker containing at least one amine nitrogen or Y is a para-aminobenzyl alcohol linker; Z is CH 3 or CF 3 ; R 1 is —H, —NR 2 R 3 , —NH—C(═O)—R 4 , —NH—C(═O)—OR 4 , —CH 2 —C(═O)—NR 5 R 6 , —OR 7 , —CO 2 R 7 , C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, aryl, or heteroaryl, wherein R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each, independently, —H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, an amino acid or an oligopeptide; wherein an amine of the amino acid or oligopeptide is substituted or unsubstituted; and n is an integer from 0 to 6; or a diastereomer, enantiomer or pharmaceutically acceptable salt of the compound.
• [EN] NOVEL PRODRUGS FOR SELECTIVE ANTICANCER THERAPY<br/>[FR] NOUVEAUX PROMÉDICAMENTS POUR UNE THÉRAPIE ANTICANCÉREUSE SÉLECTIVE
  申请人：UNIV NEW YORK STATE RES FOUND

  公开号：WO2014047199A1

  公开（公告）日：2014-03-27

  The present invention provides a compound having the structure: (Formula (I)) wherein X is a therapeutic agent containing at least one amine nitogen and the amine nitrogen on the therapeutic agent covalently bonds directly to carbon α; Z is CH3 or CF3; R1 is -H, -NR2R3, -NH-C (=0) -R4, -NH-C (=0) -0R4, -CH2-C (=0) -NR5R6, -OR7, -CO2R7, C1-6alkyl, C2-6alkenyl, C2-6 alkynyl, aryl, or heteroaryl, wherein R2, R3, R4, R5, R6 and R7 are each, independently, -H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, an amino acid or an oligopeptide; wherein an amine of the amino acid or oligopeptide is substituted or unsubstituted; and n is an integer from 0 to 6; or a diastereomer, enantiomer or pharmaceutically acceptable salt of the compound.